| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
X4 Pharmaceuticals, Inc.$4.41
+0.44 (+11.11%)
C 49Pipeline Score Fair Value Biotech · Clinical
Market Cap
381.05 M
EPS
-4.54
P/E Ratio
-
Value Trade
1.61 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.50 M
R&D Expenses
15.45 M
Operating CF
-19.60 M
Total Assets
270.28 M
Total Liabilities
101.83 M
Equity
168.45 M
D/E Ratio
12,345
1.76 %
Week
-3.81 %
1 Month
32.46 %
3 Month
8.31 %
6 Month
-98.21 %
5 Year
-99.14 %
All Time
Cash Data
Cash Position
233.72 M
Monthly Burn
6.53 M
Runway
33.9 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
912.74 K
52 Week Range
1.35 - 4.83
% held by Insiders
19.5 %
% held by Institutions
82.79 %
Enterprise Value
224.58 M
Total Shares
94.27 M
Short %
5.51 %
Float Shares
88.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for X4 Pharmaceuticals, Inc.
147Total events
3Upcoming
53Tier-1 (high impact)
2017 – 2028Coverage
Upcoming catalysts 3
Event history 144
Q3 2026
◆Enrollment CompleteMavorixaforApprovedTrial
4WARD Phase 3 trial enrollment completion expected by end of Q3 2026
chronic neutropeniasource ↗
Jun 4, 2026
◆Oral PresentationPresentation
X4 Pharmaceuticals to present at 2026 Jefferies Global Healthcare Conference
May 6, 2026
▲EU ApprovalXOLREMDIApprovedEx-US Regulatory
European Commission granted marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome in the EU
WHIM syndromesource ↗
Apr 29, 2026
▲EU ApprovalXOLREMDIApprovedEx-US Regulatory
European Commission grants marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome
WHIM syndromesource ↗
Apr 29, 2026
▲CHMP Positive OpinionXOLREMDIApprovedEx-US Regulatory
CHMP positive opinion for mavorixafor in WHIM syndrome
WHIM syndromesource ↗
Apr 29, 2026
◆Trial InitiationMavorixaforApprovedTrial
Global pivotal Phase 3 trial (4WARD) evaluating mavorixafor in chronic neutropenia is ongoing
chronic neutropeniasource ↗
Q2 2026
◆EU ApprovalMavorixaforApprovedEx-US Regulatory
EC final approval decision anticipated for mavorixafor in WHIM syndrome
WHIM syndromesource ↗
Mar 17, 2026
▲CHMP Positive OpinionMavorixaforApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorization of mavorixafor for WHIM syndrome in EU
WHIM syndromesource ↗
Mar 11, 2026
Feb 27, 2026
▲CHMP Positive OpinionMavorixaforApprovedEx-US Regulatory
CHMP positive opinion recommending approval of mavorixafor for WHIM syndrome in EU
WHIM syndromesource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $570M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.5x
rNPV / MCap Top 73%
Micro Cap (rank 247 of 911)
Percentile RankX4 Pharmaceuticals, Inc. carries a moderate pipeline score (49/100), with $1.4B risk-adjusted pipeline value, led by Mavorixafor in Neutropenia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mavorixafor Small molecule | Neutropenia | Phase 3 | NCT04154488 | 90% | $1.4B | COMPLETED | 208 | - | - | Aug 27, 2024 | MODERATE_RISK | Aug 6, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
mavorixafor BreakthroughPriorityFast Track+1 | chronic neutropenia | Phase 2 | 2025-06-16 | significant increases in neutrophil counts; potential to reduce G-CSF use; clinically meaningful and durable increases in circulating neutrophils; able to reduce injectable G-CSF while maintaining ANC levels in the normal range Read More | X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) Read More | |
mavorixafor BreakthroughPriorityFast Track+1 | chronic neutropenia | Phase 2 | 2025-06-16 | significant increases in neutrophil counts; potential to reduce G-CSF use; clinically meaningful and durable increases in circulating neutrophils; able to reduce injectable G-CSF while maintaining ANC levels in the normal range Read More | X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) Read More | |
mavorixafor BreakthroughPriorityFast Track+1 | chronic neutropenia | Phase 2 | 2025-06-16 | significant increases in neutrophil counts; potential to reduce G-CSF use; clinically meaningful and durable increases in circulating neutrophils; able to reduce injectable G-CSF while maintaining ANC levels in the normal range Read More | X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XFOR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XFOR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XFORX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be accessible via a live and archived webcast on their website. X4 focuses on therapies for rare hematology diseases and is advancing mavorixafor, an approved treatment for WHIM syndrome, currently in a Phase 3 trial for chronic neutropenic disorders.
Read more →XFORX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its 4WARD Phase 3 trial for mavorixafor, which is on track for enrollment completion by Q3 2026. The European Commission granted marketing authorization for XOLREMDI, the first treatment for WHIM syndrome in the EU. Despite a net loss of $20.2 million, the company maintains a strong cash position to support its operations through 2028.
Read more →XFORX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
X4 Pharmaceuticals has received European Commission approval for XOLREMDI (mavorixafor), the first treatment for WHIM syndrome in the EU. This authorization follows a positive opinion from the EMA and is aimed at providing a new therapeutic option for patients. The company is also conducting a global Phase 3 trial for chronic neutropenia, further exploring mavorixafor's potential benefits.
Read more →XFOR▲ +18.8%on this news
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its financial results for Q4 and full year 2025, highlighting a positive opinion from the European Medicines Agency for mavorixafor's marketing authorization in the EU. The company is on track to complete enrollment in its pivotal 4WARD Phase 3 trial for chronic neutropenia by Q3 2026. Despite a significant operating loss, X4 has a cash runway through 2028, allowing continued development of its therapies.
Read more →XFOR▲ +5.1%on this news· ran to +25% by day 3
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026. The event will showcase the company's commitment to improving the lives of patients with rare hematology diseases. X4 is currently conducting a pivotal Phase 3 trial for its drug mavorixafor, which has received FDA Fast Track designation.
Read more →XFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, consisting of options to purchase 24,000 shares of common stock, are intended to attract new talent. The options have a ten-year term and an exercise price equal to the stock's closing price on the grant date. X4 is known for its focus on therapies for rare hematology diseases.
Read more →XFOR▲ +5.8%on this newsshared move
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
X4 Pharmaceuticals has received a positive opinion from the EMA CHMP recommending marketing authorization for mavorixafor to treat WHIM syndrome in the EU. This therapy, which addresses a significant unmet medical need, is expected to be the first of its kind in Europe. The final decision from the European Commission is anticipated in the second quarter of 2026.
Read more →XFORX4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
X4 Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The management team will hold a fireside chat and is available for one-on-one meetings with investors. The event highlights X4's commitment to advancing therapies for rare hematology diseases, including their marketed product, mavorixafor.
Read more →XFORX4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference from November 10-12, 2025. The management team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one investor meetings. A webcast of the chat will be accessible on the company's website.
Read more →XFOR▼ -10.6%on this newsshared move
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its Q3 2025 financial results, highlighting a renewed focus on the 4WARD Phase 3 trial for mavorixafor in chronic neutropenia. The company achieved $240.3 million in financing, extending its cash runway to 2028. However, it also reported a net loss of $29.8 million for the quarter, indicating ongoing financial challenges.
Read more →XFORX4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
X4 Pharmaceuticals has successfully closed its public offering, raising approximately $155.3 million. The offering included 52,844,000 shares of common stock and pre-funded warrants. The full exercise of the underwriters' option to purchase additional shares reflects robust demand. The company aims to advance therapies for rare hematology diseases.
Read more →XFOR▲ +23%on this newsshared move
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
X4 Pharmaceuticals announced the pricing of a $135 million underwritten public offering of 45,860,000 shares at $2.90 each. The proceeds will support the Phase 3 development of mavorixafor for chronic neutropenic disorders. The offering is set to close on October 27, 2025, pending customary conditions. X4 has also granted underwriters an option for additional shares.
Read more →XFOR▲ +23%on this newsshared move
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
X4 Pharmaceuticals has announced a proposed underwritten public offering of its common stock and pre-funded warrants. The proceeds will support the Phase 3 development of mavorixafor for chronic neutropenic disorders. The offering is contingent on market conditions, and the company has engaged several financial partners to manage the process.
Read more →XFOR▼ -5.3%on this news
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
X4 Pharmaceuticals has announced a strategic restructuring to enhance operational efficiency and align resources with its long-term goals. This includes a 50% workforce reduction, expected to save approximately $13 million annually. The company aims to focus on completing the 4WARD Phase 3 trial for chronic neutropenia, with new leadership overseeing clinical development.
Read more →XFOR▼ -12.6%on this news
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for new executive officers. The grants include stock options for Dr. Adam Craig, Mr. John Volpone, and Mr. David Kirske, with varying vesting schedules and exercise prices. This move follows a recent $85 million private placement, aligning executive ownership with company goals.
Read more →XFOR▲ +13.6%on this newsshared move
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
X4 Pharmaceuticals has successfully closed an upsized private placement, raising $85 million through the sale of shares and warrants. The offering was led by Coastlands Capital and included several prominent investors. The funds will be used for the continued development of mavorixafor, aimed at gaining additional approval for chronic neutropenia and supporting the commercialization of WHIM.
Read more →XFOR▲ +81.7%on this news· ran to +106% by day 1shared move
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
X4 Pharmaceuticals has announced a $60 million PIPE financing led by Coastlands Capital, aimed at supporting the development of its drug mavorixafor. Concurrently, the company has undergone significant management changes, appointing Dr. Adam Craig as Executive Chairman and others from CTI BioPharma. The financing is expected to close on August 13, 2025, and will fund further development and commercialization efforts.
Read more →XFORX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
X4 Pharmaceuticals presented positive Phase 2 trial data for mavorixafor at the EHA Congress. The trial showed significant increases in neutrophil counts and the potential to reduce G-CSF use. These findings bolster confidence in the ongoing Phase 3 trial, which aims to further evaluate mavorixafor's efficacy in chronic neutropenia.
Read more →XFOR▼ -13%on this news· ran to -25% by day 3
This presentation including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer sessions and
X4 Pharmaceuticals presented forward-looking statements regarding the advancement of mavorixafor to treat chronic neutropenia and WHIM syndrome. The company highlighted the approval of mavorixafor in the U.S. and its strategy to expand global reach through partnerships. However, potential risks include challenges in regulatory approval, financial resources, and uncertainties in clinical trial outcomes. Ongoing efforts will focus on the 4WARD trial and maximizing the commercial potential of their therapy.
Read more →XFOR▼ -7%on this news· ran to -28% by day 3
X4 Pharmaceuticals Announces Reverse Stock Split
X4 Pharmaceuticals has announced a one-for-thirty reverse stock split set to take effect on April 28, 2025, in response to a Nasdaq deficiency letter regarding its minimum bid price. This action is intended to increase the stock price and comply with Nasdaq listing rules. Currently, X4 faces risks related to its stock price performance, but the company remains focused on developing therapies for rare immune system diseases. The reverse stock split is seen as a necessary step towards regaining compliance with market listing requirements.
Read more →XFOR▼ -10.8%on this news· ran to -24% by day 3
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia
X4 Pharmaceuticals has announced a strategic restructuring to focus on advancing mavorixafor for chronic neutropenia. This involves key workforce reductions and a shift in capital spending, including a 30% reduction in staff. The company has fully enrolled participants in a pivotal Phase 3 trial and expects to streamline spending to extend its cash runway into the first half of 2026. The CEO emphasized the aim to promote operational efficiency while supporting the WHIM syndrome community.
Read more →XFOR▼ -33%on this news· ran to -46% by day 3
Forward-Looking Statements This presentation including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any quest
X4 has provided an update on its ongoing Phase 2 clinical trial for mavorixafor, approved by the FDA for treating WHIM syndrome. The company is actively preparing for the commercialization of XOLREMDI, noting both the positive reception of the first patients on the product and the substantial funds raised for continued operations. However, the presentation highlighted significant risks regarding market adoption, potential revenue generation, and the actual patient population size that may limit commercial success. X4 emphasized the importance of the upcoming results from the ongoing clinical programs and the anticipated market opportunities.
Read more →XFOR▼ -6.4%on this news
Document Exhibit-99.1 X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of
X4 Pharmaceuticals announced FDA approval of XOLREMDI (mavorixafor) capsules, the first treatment for WHIM syndrome, a rare immune disorder. This approval follows a Breakthrough Therapy designation and the positive outcomes from the 4WHIM Phase 3 clinical trial, aiming to increase neutrophil and lymphocyte levels in patients. The company also introduced X4Connect, a support program for patients managing treatment. While the approval represents a significant advancement for the WHIM community, XOLREMDI may have contraindications and potential adverse side effects.
Read more →XFOR▲ +9.3%on this news· ran to +29% by day 3
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of
X4 Pharmaceuticals announced that the FDA has accepted its New Drug Application for mavorixafor, designed to treat WHIM syndrome, on October 31, 2023. The FDA granted Priority Review, setting a PDUFA target action date for April 30, 2024. The NDA is supported by positive findings from the 4WHIM Phase 3 trial, which met primary endpoints and demonstrated mavorixafor's potential efficacy and safety. If approved, mavorixafor could be the first treatment for WHIM syndrome, a rare immunodeficiency condition with no current therapies.
Read more →XFOR▼ -5.2%on this news
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors BOSTON
X4 Pharmaceuticals has appointed R. Keith Woods as an independent director on its Board of Directors, enhancing the company's leadership with his extensive background in life sciences. Woods previously served as COO at argenx and has over 30 years of experience in commercialization and operations. He expressed enthusiasm about joining X4 at a pivotal time, following the recent U.S. regulatory submission for mavorixafor, a drug aimed at treating rare immune system diseases. The company's focus on improving treatment options aligns with Woods' expertise, potentially driving future growth and innovation.
Read more →XFOR▲ +15.8%on this news· ran to +45% by day 1
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market X4 WHIM Phase 3 clinical data webinar to be held today at 4 pm
X4 Pharmaceuticals, Inc. has announced a $65 million private placement of common stock to institutional investors, with an expected closing date of May 18, 2023. This funding will be utilized for the continued development of mavorixafor, its lead candidate, and for general corporate purposes. Additionally, the company will present data from its pivotal Phase 3 clinical trial on mavorixafor today. The financing reflects strong support from both new and existing investors, while also highlighting the risks associated with the transaction's registration process.
Read more →XFOR▼ -7%on this news· ran to -28% by day 3
X4 Pharmaceuticals Announces Proposed Public Offering BOSTON
X4 Pharmaceuticals Announces Proposed Public Offering BOSTON, Dec. 06, 2022 (GLOBAL NEWS WIRE)- X4 Pharmaceuticals, Inc. (Nasdaq XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced
Read more →XFOR▲ +40.2%on this news· ran to +92% by day 3
durability, safety, and tolerability of mavorixafor in a larger CN patient population. We anticipate this amended trial to begin generating additional clinical data in the first half of 2023." Key highlights from the Pha
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN) 100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil coun
Read more →XFOR▲ +9.7%on this news· ran to +24% by day 3
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months BOSTON, Mass., June 30, 2022 - X4 Pharmaceuticals, Inc. (Nasdaq XFOR), a leader in the discovery and development of novel CXCR4-targ
Read more →XFOR▼ -5.9%on this news
Document EX 99.1
Document EX 99.1
Read more →XFORDocument X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton BOSTON, Mass., October 1, 2020 - X4 Pharmaceuticals, Inc. (Nasdaq XFOR), a leader in the discovery and development of novel therapies targeting diseases resultin
Read more →XFORX4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants Cambridge, MA
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants Cambridge, MA November 25, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel the
Read more →XFORX4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights Received orphan drug designation from the European Commission for mavorixafor for treatment of WHIM Syndrome Reported positiv
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights Received orphan drug designation from the European Commission for mavorixafor for treatment of WHIM Syndrome Reported positive data from Phase 2a clinical trial of mavorixafor in comb
Read more →XFORX4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients Subgroup exceeds target of 50% improvement in median progressi
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients Subgroup exceeds target of 50% improvement in median progression-free survival 12% of patients remain on combination tr
Read more →XFORof X4 Pharmaceuticals, Inc. s (formerly Arsanis, Inc.) Amendment No. 1 to the Current Report on Form 8-K filed on
X4 MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of X4 Pharmaceuticals Inc. ( X4 ) s financial condition and results of operations together with X4 s consolidated financial statements
Read more →XFORX4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome Global 4WHIM trial marks first-ever Phase 3 study in patients with WHIM syndrome Cambridge, MA
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome Global 4WHIM trial marks first-ever Phase 3 study in patients with WHIM syndrome Cambridge, MA June 26, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage
Read more →XFORX4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants Cambridge, MA
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants Cambridge, MA April 12, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of ra
Read more →XFORX4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants Cambridge, MA
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants Cambridge, MA April 11, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare
Read more →XFORDESCRIPTION OF THE BUSINESS OF X4 PHARMACEUTICALS, INC. Overview We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of ra
DESCRIPTION OF THE BUSINESS OF X4 PHARMACEUTICALS, INC. We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. Our pipeline is comprised of potentially first-in-cla
Read more →XFORForward Looking Statements Certain statements in this presentation, particularly statements relating to: our plans for, or progress, scope, cost, duration or results or timing for the initiation, completion or availabili
April 2019 RARE DISEASES RARE DISEASES INNOVATE 4 Exhibit 99.1 Forward Looking Statements Certain statements in this presentation, particularly statements relating to: our plans for, or progress, scope, cost, duration or results or timing for the initiation, completion or avai
Read more →XFORX4 Pharmaceuticals Completes Merger with Arsanis - Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases Cambridge, MA
X4 Pharmaceuticals Completes Merger with Arsanis - Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases Cambridge, MA March 13, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharm
Read more →XFORArsanis, Inc. and X4 Pharmaceuticals, Inc. Conference Call Tuesday, November 27 th , 2018 Arsanis, Inc. and X4 Pharmaceuticals, Inc. Conference Call Tuesday, November 27 th , 2018 Operator: Good day, ladies and gentlemen
Arsanis, Inc. and X4 Pharmaceuticals, Inc. Tuesday, November 27th, 2018 Operator: Good day, ladies and gentlemen, and welcome to the Arsanis and X4 Pharmaceuticals Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and
Read more →XFORForward Looking Statements Certain statements in this communication regarding the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and consummation o
Arsanis and X4 Pharmaceuticals Merger November 27, 2018 Exhibit 99.1 Forward Looking Statements Certain statements in this communication regarding the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and co
Read more →XFORArsanis Reports Financial Results for Third Quarter 2018 WALTHAM, Mass. and
Arsanis Reports Financial Results for Third Quarter 2018 WALTHAM, Mass. and VIENNA, Austria - November 9, 2018 - Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious d
Read more →XFORArsanis Reports Financial Results for Second Quarter 2018 WALTHAM, Mass. and
Arsanis Reports Financial Results for Second Quarter 2018 WALTHAM, Mass. and VIENNA, Austria - August 13, 2018 - Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious d
Read more →XFORArsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100 Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clini
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100 Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clinical Trial Dataset Arsanis to Continue Focus on Developme
Read more →XFORArsanis Reports Business Highlights and Financial Results for First Quarter 2018 ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June WALTHAM, Mass. and
Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June WALTHAM, Mass. and VIENNA, Austria - May 10, 2018 - Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focu
Read more →XFORArsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Commenced Phase 2 trial of lead program ASN100 Completed initial public offering and concurrent private placement Completed Series D
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 Commenced Phase 2 trial of lead program ASN100 Completed initial public offering and concurrent private placement Completed Series D financing supported by major healthcare investors Initia
Read more →Competitive Position
How XFOR ranks across every disease it competes inCompetitive Position is a premium feature
See how XFOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial